South Korean artificial intelligence company Lunit has struck a five-year partnership with Starvision Service GmbH, Germany’s largest private radiology network, solidifying its expansion into Europe’s healthcare market.
Lunit, which develops AI solutions for early-stage cancer detection and treatment optimization, will deploy its imaging technologies across Starvision’s 79 locations in seven German federal states.
The deal includes implementation of Lunit’s chest X-ray analysis, mammography interpretation, digital breast tomosynthesis, and fracture detection tools. Initial deployments in Hamburg and Bavaria are already supporting approximately 120,000 breast cancer screenings annually.
“This strengthens diagnostic confidence and gives us more time to focus on what truly matters: the individual care of our patients,” said Uwe Pfeifer, CEO of Starvision.
For Lunit, which has secured FDA clearance for several AI diagnostic tools and recently partnered with AstraZeneca for lung cancer diagnostics, the German deal represents significant market expansion. The company expects 100 billion won ($74 million) in revenue for 2025, quadrupling last year’s figures.
The agreement allows additional Starvision locations to adopt Lunit’s technology at any time, with several other German healthcare providers expressing interest in similar partnerships.
